November 12, 2024 7:57am

Can investors see the light on the approach process - today?

Earnings: Agenus (AGEN), Sage Therapeutics (SAGE), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM) and Voyager Therapeutics (VYGR)

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

MY Pre-Open Thoughts:  2 Negative and 1 Sell into Strength Indications

Never leave an investor uninform

RegMed Investors (RMi) Closing Bell: investor appetite? … https://www.regmedinvestors.com/articles/13693

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Tuesday: The pre-open Dow futures are DOWN -0.09% (-41 points), the S&P futures are DOWN -0.11% or (-6 points) and the Nasdaq futures are -0.08% or (-16 points)

  • Stock futures slipped Tuesday, 11/12/2024,
  • European markets were lower,
  • Asia-Pacific markets fell.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed UP +304.14 points or +0.69%, the S&P closed UP +5.81 points or +0.10% while the Nasdaq closed UP +11.99 points or -0.06%
  • Investors will watch Tuesday for economic data on small businesses due in the morning.
  • They’ll also monitor commentary from Federal Reserve officials including Fed Governor Christopher Waller and Minneapolis Fed President Neel Kashkari scheduled throughout the day. <CNBC>

Economic Data Docket: New York Fed one-year inflation expectations, October (3.0% previously)

 

Q4/24: November 3 negative and 4 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength


Monday, Friday, Thursday, Wednesday, Tuesday, Monday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)  

Lenz Therapeutics (LENZ) closed up +$0.68 after Friday’s +$2.54, Thursday’s +$0.30, Wednesday’s +$3.58 with a negative -$1.12 or -3.13% aftermarket

 

Negative Indications:

Monday, Friday, Thursday, Wednesday, Tuesday, and last Monday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)  

Beam Therapeutics (BEAM) closed down +$3.29 after Friday’s +$0.96 with a negative -$0.06 or -0.20% pre-open

Vericel (VCEL) closed up +$2.78 after Friday’s +$3.97, Thursday’s +$1.99, Wednesday’s +$3.29 and last Tuesday’s +$0.38 after the previous Monday’s +$0.38 with a negative -$1.117 or -2.06% aftermarket

 

 

The BOTTOM LINE:Aare we hitting a pause as earnings and econs shift the table plate?

Instead of the salt shaker, is fear gauge replacing the pepper as the CBOE Volatility Index stayed lower after the S&P 500 and the Dow both hit records to start the week. The VIX held at around 15, slightly lower than it was just after the election last week.

Focus is starting to turn to Wednesday's report on the consumer price index for October, watched for signs that inflation is cooling as the Fed desires.

  • Retail sales data on Thursday is another key input for the Fed's policy decision at its December meeting — its last before the Trump administration takes office. <Yahoo Finance?

 

Ranking the end of October:     

  • 11/11- Moday closed positive with 23 incliner, 11 decliners and 1 flat
  • 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
  • 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
  • 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
  • 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.